Urine tenofovir-monitoring predicts HIV viremia in patients treated with high genetic-barrier regimens.

ABSTRACT:

Objective

Access to viral load measurements is constrained in resource-limited settings. A lateral flow urine tenofovir (TFV) rapid assay (UTRA) for patients whose regimens include TFV offers an affordable approach to frequent adherence monitoring.

Design

We conducted a cross-sectional study of patients to assess the utility of UTRA to predict virologic failure, defined as a viral load greater than 400 copies/ml.

Methods

We assessed urine TFV among 113 participants at increased risk of viral failure (who had previous viral failure on this regimen or had previously been ≥30 days out of care), comparing low genetic-barrier efavirenz (EFV) regimens (n = 60) to dolutegravir (DTG)-boosted or ritonavir-boosted protease inhibitor (PI/r)-based high genetic-barrier regimens (n

SUBMITTER: van Zyl G 

PROVIDER: S-EPMC9623472 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature